So feeling good about the broader momentum there. On the seasonality question, the trend I talked about earlier with Cologuard, there’s a similar trend with mammography. Fewer women seek out mammograms during the summer, which means a fewer breast cancer diagnoses. Obviously, Oncotype is typically ordered after breast cancer diagnosis. So that trend Q2 to Q3, that’s kind of what you’d expect, a slowdown in Q2 to Q3 and then a stronger Q4.
Operator: We’ll take our next question from Mark Massaro with BTIG.
Mark Massaro: Hey guys, thanks for the questions and great to see everyone in Madison. So thanks for hosting that. I wanted to ask on MRD. I know that you’re planning to launch your initial tumor-informed Oncodetect MRD test in colorectal cancer, like you guys said in Q4 2023. Can you give me a sense for — I’m pretty sure that this is your — the test that you’ve been developing for some time now. I’m just curious where the Broad Institute comes in? Because, in that PR, you talk about the MAESTRO program and how this can detect thousands of patient-specific mutations. Obviously, MRD is early. So I’m just curious if you can just give us your sense for your confidence level between your first-gen product and maybe the second-gen product and/or your confidence level on sticking with tumor-informed versus switching over to tumor naive?
Kevin Conroy: The MAESTRO technology that we exclusively licensed from the Broad Institute will be used in the next generation of MRD. So the test that will be available at the end of this year is the base exact version of the technology. Think of that Broad technology as an extension, an enhancement using more mutations, creating a greater sensitivity at a similar specificity. And that technology would be used in the studies that we’ve talked about, including the West German Study Group, WGS, and the NSABP, which is the CORRECT-II study. So you have the Triad study and the CORRECT-II studies, which would use that next-generation version of our MRD test.
Operator: We’ll take our next question from Andrew Cooper with Raymond James.
Andrew Cooper: Hey, everybody. Thanks for the question and nice quarter for sure. I guess maybe first tagging on to one that I think Andrew — other Andrew asked. Thinking about the health system backlog, is there a point where these health systems have worked that down and what’s their ability to sort of refill that backlog? Is it an ongoing dynamic versus I think you’ve talked about in the past a little bit of, oh shoot, we need to get more folks screened for some of these rating dynamics that can make it a little bit seasonal. So just help us think about the runway there. What happens once they’ve worked that lower and how the trajectory goes for those that get a little bit more mature once they’re onboarded?
Everett Cunningham: Yeah. I’ll touch on that. To me, I — and if I said backlog, I think when we’re talking to health systems, confident, it’s a capacity issue. And they just know that they can’t do it alone. They have a — they have a screening population. They have quality metrics that they need to hit. And they know with that screening population, they cannot do it alone with the amount of GI physicians that they have and just their workload, that’s why they’re coming to us. They’re coming to us for help. They know that Cologuard is a great first-line option. And that’s where we’re coming in with not just Cologuard, but we’re coming in with our wraparound services that help them with compliance. We’re coming in with marketing tools and efforts that proactively go out to these patients. It’s like a surround sound that really helps them with getting their patients screened and also hitting their quality metrics, which benefits that health system tremendously.
